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Liver transplantation is now the standard treatment for end-stage liver disease. Given the shortage of liver donors and
the progressively higher number of patients waiting for transplantation, improvements in patient selection and optimization
of timing for transplantation are needed. Several solutions have been suggested, including increasing the donor pool; a fair
policy for allocation, not permitting variables such as age, gender, and race, or third-party payer status to play any role; and
knowledge of the natural history of each liver disease for which transplantation is offered. To observe ethical rules and
distributive justice (guarantee to every citizen the same opportunity to get an organ), the “sickest first” policy must be used.
Studies have demonstrated that death has no relationship with waiting time, but rather with the severity of liver disease at
the time of inclusion. Thus, waiting time is no longer part of the United Network for Organ Sharing distribution criteria.
Waiting time only differentiates between equally severely diseased patients. The authors have analyzed the waiting list
mortality and 1-year survival for patients of the State of São Paulo, from July 1997 through January 2001. Only the
chronological criterion was used. According to “Secretaria de Estado da Saúde de São Paulo” data, among all waiting list
deaths, 82.2% occurred within the first year, and 37.6% within the first 3 months following inclusion. The allocation of
livers based on waiting time is neither fair nor ethical, impairs distributive justice and human rights, and does not occur in
any other part of the world.
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Liver transplantation is now the
standard treatment for end-stage liver
disease. However, given the shortage
of liver donors and the progressively
higher number of patients on the wait-
ing list for liver transplantation, im-
provements in patient selection and
optimization of timing for transplan-
tation are needed1,2.
The first step towards improving
the selection process is to introduce
greater uniformity of the patient selec-
tion process between different trans-
plant programs. The earlier the trans-
plant is done in the course of progres-
sive liver disease, the better are the op-
erative and immediate postoperative
outcomes. On the other hand, organs
have become scarce relative to the
number of potential recipients as the
number of transplant programs has
grown. Because of the uncertainty of
organ availability, patients are placed
on waiting lists earlier to ensure receiv-
ing an organ before serious deteriora-
tion has occurred. As of 1998, the
Child-Turcotte-Pugh (CTP) classifica-
tion has been used when minimal list-
ing criteria were defined3. Even so, pa-
tients may wait for months or even
years for an organ, during which time
their health and candidacy may dete-
riorate. To solve this problem, several
improvements are needed. First, effec-
tive steps must be taken to improve the
size of donor pool4,5. Second, a fair6
policy of organ allocation that maxi-
mizes the utilization of available or-
gans must be agreed to by all, not per-
mitting a number of models that use
politically charged variables such as
age, gender, and race, or third-party
payer status, which would discriminate
against some groups of patients and
therefore could not be incorporated in
a model to be used nationally to se-
lect patients for organ allocation7-9.
Third, the natural history of each liver
disease must be defined for the differ-
ent diagnoses for which transplanta-
tion is offered. And finally, to observe
ethical rules and distributive justice
(guarantee to every citizen the same
opportunity to get an organ) the
“sickest first” policy10 should be used.
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However, liver transplantation is
still a risky process. Thus, one should
consider the morbidity and mortality
(rejection, infections, biliary problems,
primary nonfunction, etc.) when indi-
cating a liver transplantation. Some
patients may remain alive and stable
on conservative medical or surgical
therapy1.
At the same time, since long-term
survival improves after liver transplan-
tation, cardiovascular complications,
among others, are emerging as a ma-
jor cause of morbidity and mortality11.
Additionally, recurrence of the liver
disease (hepatitis B and C, primary bil-
iary cirrhosis, primary sclerosing
cholangitis, autoimmune hepatitis, or
alcoholic cirrhosis), de novo malig-
nancies, and bone disease should be
taken into account when determining
suitability for liver transplantation12-18.
Liver transplantation has evolved
over the past 30 years from a rather dra-
matic and desperate surgical rescue of
patients with end-stage liver disease to
a commonplace treatment modality,
with nearly 5,000 liver transplants be-
ing performed yearly in the United
States19. Indeed, some 40,000 patients
in the United States have undergone
liver transplantation in the past decade.
Today in the USA, survival after liver
transplantation is 90% within 1 year
and approximately 75% at 5 years12.
Over the past few years, donor organ al-
location policy and liver allocation in
particular have been intensely scruti-
nized and criticized by the press and by
the federal government20. Much of the
criticism has focused on the wide vari-
ations in the time that candidates for
liver transplantation must wait for an
organ and on the geographic correla-
tion of these differences21. However,
many liver specialists have argued that
waiting time for liver transplantation is
not a good measure of a program’s per-
formance22-24.
In April 1998, the US Department
of Health and Human Services (DHHS)
issued the final ruling, in which the
principles of allocation policies and
procedures were defined in order to
guide the Organ Procurement and
Transplant Network (OPTN) 25. These
rules included allocation of organs
among transplant candidates follow-
ing a medical urgency criterion that
minimized the role of waiting times
and avoided futile transplantation
while promoting efficient management
of organ placement. A subsequent re-
port from the Institute of Medicine,
commissioned by USA Congress, con-
cluded that the liver allocation system
based in waiting times was not fair26.
More recently, Freeman et al.30
studied factors associated with the risk
for mortality once an individual is
placed on the liver transplant waiting
list and how this risk relates to center-
specific waiting times and transplant
activity. A Cox proportional hazard
model was used to calculate the 2-year
mortality risk for a cohort of 16,414
registrants added to the United Net-
work for Organ Sharing liver transplant
waiting list between January 1, 1997,
and December 31, 1997. After control-
ling for confounding variables, they
calculated the mortality risk for
centers, organ procurement organiza-
tions (OPOs), and states. The relation-
ship between center-specific waiting
list mortality risk and median waiting
time or transplant activity was deter-
mined by linear regression. In
multivariate analysis, higher initial
medical urgency status (relative risk
[RR] = 12.8; P <.001), increasing age
(RR = 1.2; P <.001), black ethnicity
(RR = 1.29; P <.001), history of previ-
ous transplant (RR = 1.2; P =.009),
smaller center size (RR = 1.39; P
=.008), and certain liver diagnoses
were associated with significantly in-
creased waiting list mortality. There
were significant variations in 2-year
waiting list mortality risk among
centers, OPOs, and states. However,
when stratified by medical urgency
status at waiting list entry, center-spe-
cific waiting time and transplantation
rates accounted for almost none of the
center-specific waiting list mortality.
These investigators concluded that
waiting time and center transplant
rates should not influence liver allo-
cation policy27.
Thus, the Freeman study results
clearly indicate that the United Net-
work for Organ Sharing (UNOS) medi-
cal urgency categories, as defined in
his study, have a significant relation-
ship to the risk for death on the list.
Despite the methodologic differences,
these 2 separate and independent stud-
ies confirm that status-specific (IOM
analysis) and patient-specific (Free-
man’s study) waiting times are not re-
lated to the risk of death on the wait-
ing list and should discredit the util-
ity of waiting times as a criterion for
liver allocation. Using medical ur-
gency as the primary criterion for de-
termining the selection of liver trans-
plant recipients is sometimes referred
to as the “sickest first” policy28.
A recent mandate emphasizes the
use of the severity of liver disease to
determine priorities in allocating or-
gans for liver transplantation and ne-
cessitates a disease severity index
based on generalizable, verifiable, and
easily obtained variables26.
Before this development, on Feb-
ruary 21, 2000, Freeman et al., imple-
mented a variance to the UNOS liver
allocation policy that redefined status
2A with much more rigid, definable
criteria and prioritized status 2B pa-
tients by using a continuous medical
urgency score based on the Child-
Turcotte-Pugh score and other medical
conditions. In this system, waiting
time is used only to differentiate sta-
tus 2B candidates with equal medical
urgency score. A continuous medical
urgency scoreis particularly problem-
atic for patients classified as status 2B,
who form the largest group of patients
undergoing liver transplantation
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(56%) and who exhibit a broad range
of liver disease severity29.
Comparing the 6-month period
(period 1; n = 67) before implementa-
tion of this system to 6-month period
after implementation (period 2; n =
75), there was a significant reduction
in the number of transplants performed
for patients listed as status 2A (46.3%
to 14.7%; P = .002) and an increase in
the number of patients listed as status
2B who received transplants (44.8% to
70.7%; P = .10). Most dramatically,
there was a 37.1% reduction in over-
all deaths on the waiting list, from 94
deaths in period 1 to 62 deaths in pe-
riod 2 (P = .005), with the most sig-
nificant reduction for patients removed
from this list at status 2B (52 v 18 pa-
tients; P = .04). There were 3 postop-
erative deaths in each period, with only
1 graft loss in period 2. Status 2B pa-
tients with the greatest degree of medi-
cal urgency received transplants with-
out multiple peer reviews of requests
for elevation to 2A status. In summary,
the continuous medical urgency score
system allocates donor livers much
more fairly to those in medical need
and reduces waiting list mortality with-
out sacrificing efficacy30,31.
More recently, Kamath, et al.33
adapted a model designed to predict
poor survival in patients undergoing
transjugular intrahepatic portosystemic
shunts (TIPS) to treat refractory ascites32.
This system, called the Model for End-
Stage Liver Disease (MELD) utilizes se-
rum bilirubin and creatinine levels, in-
ternational normalized ratio (INR) for
prothrombin time, and the etiology of
the liver disease. The model’s validity
was tested in 4 independent data sets,
including (1) patients hospitalized for
hepatic decompensation (referred to as
“hospitalized” patients), (2) ambulatory
patients with noncholestatic cirrhosis,
(3) patients with primary biliary cirrho-
sis (PBC), and (4) unselected patients
from the 1980s with cirrhosis (referred to
as “historical” patients). In these pa-
tients, the model’s ability to classify pa-
tients according to their risk of death was
examined using the concordance (c)-sta-
tistic. The MELD scale performed well
in predicting death within 3 months,
with a c-statistic of 0.87 for hospitalized
patients, 0.80 for noncholestatic ambu-
latory patients, 0.87 for PBC patients,
and 0.78 for historical cirrhotic patients.
Individual complications of portal hy-
pertension had minimal impact on the
model’s predictive power (range of im-
provement in c-statistic: <.01 for spon-
taneous bacterial peritonitis and variceal
hemorrhage to ascites: 0.0 to 0.03). The
MELD scale proved to be a reliable
measure of mortality risk in patients with
end-stage liver disease and suitable for
use as a disease severity index to deter-
mine organ allocation priorities.
WHAT  IS  MELD?
The Model for End-Stage Liver
Disease (MELD)34 is a numerical scale,
ranging from 6 (less ill) to 40 (gravely
ill), that has been used as an organ al-
location criterion for adult liver trans-
plant candidates in the USA, as of Feb-
ruary 2002. It gives each individual a
‘score’ (number) based on how urgently
he or she needs a liver transplant within
the next 3 months. The number is cal-
culated using a formula that includes 3
routine lab test results:
• bilirubin, which measures how ef-
fectively the liver excretes bile;
• INR (prothrombin time), which
measures the liver’s ability to make
blood clotting factors; and
• creatinine, which measures kidney
function. (Impaired kidney func-
tion is often associated with severe
liver disease.)
The MELD score replaced the pre-
vious Status 2A, 2B, and 3 categories.
Upon initiating the use of the MELD
criterion, the status 1 category (pa-
tients who had acute liver failure and
a life expectancy of less than 7 days
without a transplant) remained in place
as the highest priority for receiving an
organ, and is not affected by the use
of the MELD system.
A patient’s score may go up or
down over time depending on the sta-
tus of his or her liver disease. Many
patients have their MELD score as-
sessed a number of times while they are
on the waiting list. This helps ensure
that donated livers go to the patients
in greatest need at that moment.
A patient who does not have a
MELD score that, in the judgment of
his transplant physician, appropriately
reflects the patient’s medical urgency
may nevertheless be assigned to a
higher MELD score upon application
to and justification by the appropriate
Regional Review Board (RRB).
Special cases are HCC (hepatocel-
lular carcinoma), HPS (hepatopul-
monary syndrome), familial amyloido-
sis, and some other cases not specified.
Applications for MELD score excep-
tions require prospective RRB ap-
proval. The listing center completes a
MELD Exception Application online.
UNetSM shows completed applications
as ‘Pending’. The UNOS then blinds
patient and center information, and re-
leases the blinded application to RRB
members for medical review. UNetSM in-
dicates ‘Submitted to RRB’. When the
RRB has reached a majority vote,
UNetSM indicates a majority decision. If
the requested higher MELD score is ap-
proved, the MELD score used by the
liver-matching system is immediately
updated on the candidate’s waiting list
registration. If the requested higher
MELD score is not approved, the center
can choose to appeal or not appeal.
HCC  MEDICAL  CRITERIA
Applications involving HCC do
not require prospective RRB ap-
proval: UNetSM assigns a MELD score
of 15% mortality risk for HCC patients
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with tumor size < 2 cm, or MELD score
of 30% mortality risk for HCC patients
with tumor size > to 2 cm, or multiple
lesions with the largest being < 3 cm.
INITIAL REGISTRATION
CRITERIA
Patients need to undergo an evalu-
ation of the number and size of tumors.
The assessment must include ultra-
sound of the liver, CT or MRI of the
abdomen and chest, and a bone scan
AND one of the more invasive proce-
dures listed in policy. For a tumor > 1
cm, the radiological assessment is ad-
equate. Every 3 months, the patient
will receive additional MELD points
equivalent to a 10% increase in pre-
transplant mortality as assigned. The
listing center must enter an updated
MELD Score Exception Application
every 3 months in order to receive ad-
ditional HCC points.
The routine of implementation has
included status changes during the
first 30 days, after the first 30 days, and
after 1 year (Table 1).
Lab values must be updated ac-
cording to the recertification schedule
above; otherwise, patients will auto-
matically revert to the previous lower
MELD score. If there was no previous
score available, patients will be as-
signed a score of 6. UNetSM will not ac-
cept lab dates outside the ranges
shown. For patients with MELD scores
> 18, UNOS Compliance Examiners
will call transplant coordinators to
alert them before patient scores are au-
tomatically adjusted. Calls have been
recorded for quality assurance.
HOW  IS  WAITING  TIME  USED?
Waiting time is only used to break
ties among patients with same MELD
scores and blood type compatibility.
Waiting time is carried backwards
but not forwards. When patient moves
to a higher MELD score, a new wait-
ing time clock starts. If patient moves
to lower MELD score, time accumu-
lated at the higher score or status 1 is
included.
HOW  HAS  MELD  AFFECTED
ALLOCATION  POLICY?
Status 2A was eliminated from the
allocation algorithm 30 days after
MELD implementation. Any time
spent in 2A during said period (up to
a total of 30 days) was associated with
the patient’s first calculated MELD
score at the end of the transition pe-
riod or upon downgrade from a 2A to
MELD during the transition period.
The adult status 1 definition was not
changed. The allocation sequence re-
mains local, followed by regional, and
then national.
“MELD has been monitored
closely since implementation, so that
necessary changes can be identified
and adopted as more data are col-
lected”34.
One drawback attributed to the
MELD model is that it only predicts
the survival rate of persons on the wait-
ing list prior to liver transplantation,
but not the chance of survival after
transplantation. However, when we
analyzed the model developed by
Malinchoc et al.32 to access patients’
prognosis following transjugular intra-
hepatic portosystemic shunt (TIPS)
procedures, we found that the same
variables were used as with the MELD
model (levels of bilirubin, creatinine,
and INR). The TIPS procedure func-
tions, in effect, like a side-to-side por-
tocaval shunt, promptly reducing por-
tal pressure. The decrease in hepatic
sinusoidal pressure decreases the risk
of variceal bleeding as well as the for-
mation of ascitis. However, by divert-
ing portal blood flow, TIPS may
worsen liver function as well as in-
crease the risk of hepatic encephalopa-
thy in these patients. Some patients do
well after TIPS, whereas others fair
poorly, and their chances of survival
might, in fact, be reduced. However, in
their elegant study, Malinchoc et al.
showed that patients with low risk (R
< 1.8, n = 65; P = 0.88) had better sur-
vival rates when compared to patients
with a higher risk (R > 1.8, n = 6; P =
0.41). Thus, although we do not have
any information regarding whether the
MELD model could be used to predict
survival after liver transplantation, the
possibility seems reasonable.
In contrast with all the above, in
São Paulo, Brazil, since July 7, 1997,
allocation priority for livers has been
based exclusively on waiting time ex-
cept in cases of fulminant hepatic fail-
ure (FHF) or re-transplantation. In the
period between July 1997 to January
2001, 2,450 patients were included on
the orthotopic liver transplant waiting
list in the city of São Paulo; waiting
time was the criterion for selection for
transplantation. Of those patients,
1,395 (56.9%) were removed from the
list (death = 595; transplanted = 589;
other = 221), and 1,052 (42.9%) re-
mained on the list. Of the 595 patients
who died on the waiting list, 489
(82.2%) died within 1 year of waiting;
224 (37.6%) died between 0 and 3
months; 115 (19.3%) between 4 and 6
months, and 150 (25.2%) between 7
and 12 months after inclusion on the
list35. Theses results corroborate the
findings of IOM and Freeman et al. that
liver transplant waiting time does not
correlate with waiting list mortality
but rather with the severity of the liver
Table 1 - How frequently do MELD data
get recertified?
Score Recertification Lab Values
≥ 25 every 7 days ≤ 48 hrs old
24-19 every 30 days ≤ 7 days old
18-11 every 90 days ≤ 14days old
≤ 10 every year ≤ 30 days old
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disease. On the other hand, when we
looked at the 589 patients who under-
went transplantation surgery, we found
that the 1-year survival rates were ex-
tremely varied among different groups
(50.0% to 82.2%)36. (Fig. 1)
The high mortality rate on the wait-
ing list in São Paulo (25.4% to 77.8%)
is striking, horrifying patients, rela-
tives, and physicians. These results
should be re-evaluated and taken into
consideration by the Brazilian Health
Service35. The allocation of livers to
patients with end-stage liver disease
based on the criterion of waiting time
is neither fair nor ethical, impares the
distributive justice and the human
rights, and does not occur in any other
part of the world10,37.
Finally, we hope that everyone
who is involved with liver transplan-
tation, including patients, doctors, au-
thorities, and members of society at
large as well, will discover by consen-
sus the way to reduce waiting list mor-
tality, saving the lives of all those pa-
tients with end-stage liver disease.
Figure 1 - Liver transplantation waiting list mortalaty - “Secretaria de Estado da Saúde de São
Paulo”.
RESUMO
SETTE Jr. H e col. - Análise crítica da
política de alocação de órgãos para
transplante de fígado no Brasil.
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lo 58(3):179-184, 2003.
Transplante hepático é tratamento
de escolha para pacientes portadores
de doença hepática em fase terminal.
Pela escassez de órgãos e número cres-
cente de receptores, seleção dos can-
didatos e otimização do momento do
procedimento são necessários. Estraté-
gias foram apontadas: aumento do nú-
mero de doadores; política justa impos-
sibilitando que idade, sexo, raça, con-
dição financeira façam diferença; co-
nhecimento da história natural de cada
doença hepática para a qual o trans-
plante hepático é indicado. Para obe-
decer aos princípios da ética médica e
de justiça distributiva (garantia a todo
cidadão a mesma oportunidade de ob-
ter um enxerto), é necessário estabele-
cer critérios de gravidade. Estudos
(Institute of Medicine e Freeman e col.)
demonstraram que tempo de lista não
tem relação direta com o número de
óbitos e sim com a gravidade dos pa-
cientes no momento da inscrição. As-
sim, nos EUA, o tempo de lista foi re-
tirado no cálculo para alocação, ser-
vindo apenas para diferenciar pacien-
tes igualmente graves. Mortalidade em
lista de espera bem como sobrevida de
um ano no Estado de São Paulo, onde
a alocação obedece critério cronológi-
co rígido desde 1997, foram analisa-
dos. Dados da Secretaria de Estado da
Saúde de São Paulo, no período de ju-
lho de 1997 a janeiro de 2001, dentre
os óbitos em lista, 82.2% ocorreram
dentro do 1o ano de lista, sendo 37,6%
nos primeiros 3 meses após a inclusão.
Alocar fígados para transplante
obedecendo critério exclusivamente
cronológico não é justo ou ético, fere
os princípios de justiça distributiva e
os direitos humanos, não encontrando
similaridade em qualquer outra parte
do mundo.
DESCRITORES: Transplante he-
pático. Critérios de alocação. Mode-
los prognósticos de sobrevida.
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